CSIMarket Company Name, Ticker, Industry, else..
 
Arcellx Inc   (NASDAQ: ACLX)
 

Arcellx Inc's Suppliers Performance

ACLX's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
ACLX Costs vs Sales of Suppliers Growth

• More on ACLX Suppliers






Arcellx Inc's Comment on Supply Chain


The company collaborates with Kite under the Kite Collaboration Agreement, whereby Kite manufactures anito-cel and assumes the costs related to CMC commercial readiness and associated capital expenses. Manufacturing costs for clinical material are shared between the company and Kite. Additionally, the company maintains partnerships with experienced CAR-T contract manufacturers for clinical materials and manufacturing services outside of the Kite agreement. The company holds IND clearance to manufacture anito-cel at its cGMP facility in Redwood City, California, for a Phase 1 trial. The manufacturing process for ARC-T cells aligns with that of anito-cel but utilizes a lentiviral vector encoding a universal ARC. SparX proteins are produced in-house for most research activities, while a third-party contract manufacturing organization (CMO) is engaged for most preclinical studies and all clinical trials. SparX proteins are generated in mammalian and microbial systems and are subject to extensive monitoring and analytical testing throughout purification.

Arcellx Inc's Comment on Supply Chain


The company collaborates with Kite under the Kite Collaboration Agreement, whereby Kite manufactures anito-cel and assumes the costs related to CMC commercial readiness and associated capital expenses. Manufacturing costs for clinical material are shared between the company and Kite. Additionally, the company maintains partnerships with experienced CAR-T contract manufacturers for clinical materials and manufacturing services outside of the Kite agreement. The company holds IND clearance to manufacture anito-cel at its cGMP facility in Redwood City, California, for a Phase 1 trial. The manufacturing process for ARC-T cells aligns with that of anito-cel but utilizes a lentiviral vector encoding a universal ARC. SparX proteins are produced in-house for most research activities, while a third-party contract manufacturing organization (CMO) is engaged for most preclinical studies and all clinical trials. SparX proteins are generated in mammalian and microbial systems and are subject to extensive monitoring and analytical testing throughout purification.







ACLX's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Arcellx Inc 6,479.07 22.29 -228.93 209
SUBTOTAL 0.00 0.00 0.00 -


Sources: Arcellx Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Arcellx Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.